VK PREMIUM responded excellently to the high demands of our investment in the biotechnology sector. I am very satisfied, as with the support of VK PREMIUM, the subsidy for the investment plan amounting to 83 million euros, which will be implemented by Theracell and Orgenesis, was approved by the Interministerial Committee for Strategic Investments.
HOME ⬅ Testimonials ⬅ Fotis Sakelaridis, CEO, THERACELL